These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 12915987)

  • 1. [Cluster-immunotherapy in seasonal allergic rhinitis: safety aspects of induction therapy with depot allergoids (Purethal)].
    Hansen I; Hörmann K; Stuck BA; Schneider-Gêne S; Mösges R; Klimek L
    Laryngorhinootologie; 2003 Aug; 82(8):558-63. PubMed ID: 12915987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety aspects of Cluster immunotherapy with semi-depot allergen extracts in seasonal allergic rhinoconjunctivitis.
    Pfaar O; Mösges R; Hörmann K; Klimek L
    Eur Arch Otorhinolaryngol; 2010 Feb; 267(2):245-50. PubMed ID: 19756683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study.
    Serrano P; Justicia JL; Sánchez C; Cimarra M; Fernández-Távora L; Orovitg A; Moreno C; Guerra F; Alvà V
    Ann Allergy Asthma Immunol; 2009 Mar; 102(3):247-52. PubMed ID: 19354072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a cluster specific immunotherapy in children with bronchial asthma and mite allergy.
    Schubert R; Eickmeier O; Garn H; Baer PC; Mueller T; Schulze J; Rose MA; Rosewich M; Renz H; Zielen S
    Int Arch Allergy Immunol; 2009; 148(3):251-60. PubMed ID: 18849616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cluster immunotherapy of persistent allergic rhinoconjunctivitis. Safety aspects of induction therapy with mite depot allergen preparations].
    Pfaar O; Mösges R; Hörmann K; Klimek L
    HNO; 2009 Nov; 57(11):1099-105. PubMed ID: 19585090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Birch pollen immunotherapy leads to differential induction of regulatory T cells and delayed helper T cell immune deviation.
    Möbs C; Slotosch C; Löffler H; Jakob T; Hertl M; Pfützner W
    J Immunol; 2010 Feb; 184(4):2194-203. PubMed ID: 20048125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis.
    Frew AJ; Powell RJ; Corrigan CJ; Durham SR;
    J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
    Kopp MV; Hamelmann E; Zielen S; Kamin W; Bergmann KC; Sieder C; Stenglein S; Seyfried S; Wahn U;
    Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of two cluster schedules for subcutaneous immunotherapy in allergic rhinitis or asthma patients sensitized to inhalant allergens.
    Pfaar O; Klimek L; Fischer I; Sieber J; Amoroso S; Moreno Aguilar C; Shah K; Mösges R
    Int Arch Allergy Immunol; 2009; 150(1):102-8. PubMed ID: 19339808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local nasal immunotherapy: efficacy and tolerability of two different administration schedules in grass pollen rhinitis.
    Senna GE; Andri G; Dama AR; Falagiani P; Andri L
    Allergol Immunopathol (Madr); 2000; 28(4):238-42. PubMed ID: 11022271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus.
    Tabar AI; Echechipía S; García BE; Olaguibel JM; Lizaso MT; Gómez B; Aldunate MT; Martin S; Marcotegui F
    J Allergy Clin Immunol; 2005 Jul; 116(1):109-18. PubMed ID: 15990782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of allergen immunotherapy in the treatment of allergic rhinitis and asthma in real life.
    Zeldin Y; Weiler Z; Magen E; Tiosano L; Kidon MI
    Isr Med Assoc J; 2008 Dec; 10(12):869-72. PubMed ID: 19160945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Side-effects of allergen-specific immunotherapy: a prospective multi-centre study.
    Winther L; Arnved J; Malling HJ; Nolte H; Mosbech H
    Clin Exp Allergy; 2006 Mar; 36(3):254-60. PubMed ID: 16499635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial.
    Kleine-Tebbe J; Ribel M; Herold DA
    Allergy; 2006 Feb; 61(2):181-4. PubMed ID: 16409193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually.
    Panzner P; Petrás M; Sýkora T; Lesná I
    Respir Med; 2008 Sep; 102(9):1296-304. PubMed ID: 18585908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An observational study on outgrowing food allergy during non-birch pollen-specific, subcutaneous immunotherapy.
    Alonso R; Enrique E; Pineda F; Basagaña M; San Miguel-Moncín MM; Bartra J; Palacios R; Cisteró-Bahíma A
    Int Arch Allergy Immunol; 2007; 143(3):185-9. PubMed ID: 17284927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative study of cluster and conventional immunotherapy schedules with dermatophagoides pteronyssinus in the treatment of persistent allergic rhinitis.
    Zhang L; Wang C; Han D; Wang X; Zhao Y; Liu J
    Int Arch Allergy Immunol; 2009; 148(2):161-9. PubMed ID: 18802361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Preventive immunotherapy].
    Boquete M; Carballada F; Expósito F; González A
    Allergol Immunopathol (Madr); 2000; 28(3):89-93. PubMed ID: 10867376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Allergen specific-IgG4 in circulating immune complexes in patients with inhalant allergy undergoing specific immunotherapy].
    Rogala B; Jarzab J; Rymarczyk B; Tłuczykont B
    Wiad Lek; 2004; 57(3-4):123-30. PubMed ID: 15307518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cluster immunotherapy in allergic rhinoconjunctivitis: review of a new therapeutic approach].
    Pfaar O; Klimek L
    Hautarzt; 2006 Oct; 57(10):875-80. PubMed ID: 16969674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.